VanEck Vectors Generic Drugs ETF
GNRX
GNRX was delisted on the 4th of April, 2019.
1 hedge funds and large institutions have $163K invested in VanEck Vectors Generic Drugs ETF in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $172K → $163K (-$8.73K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$11.4K |
GNRX Hedge Fund Activity: Q3 2018 in Review
1 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q3 2018, worth a combined $163K — down 5.1% from $172K a quarter earlier.
Fund positioning in GNRX was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was American Portfolios Advisors, cutting an estimated $11.4K.
- 1 institutional investor held VanEck Vectors Generic Drugs ETF (GNRX) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $163K of VanEck Vectors Generic Drugs ETF stock for Q3 2018, down 5.1% quarter-over-quarter.
- 0 funds opened new VanEck Vectors Generic Drugs ETF positions in Q3 2018 and 0 closed out.
- The largest VanEck Vectors Generic Drugs ETF seller in Q3 2018 was American Portfolios Advisors, an estimated $11.4K sold.
Based on aggregated 13F filings for Q3 2018.